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Abstract
Background: An approach to use multivalent dendrimer carriers for delivery of nucleoside
signaling molecules to their cell surface G protein-coupled receptors (GPCRs) was recently
introduced.
Results: A known adenosine receptor (AR) agonist was conjugated to polyamidoamine (PAMAM)
dendrimer carriers for delivery of the intact covalent conjugate to on the cell surface. Depending
on the linking moiety, multivalent conjugates of the N6-chain elongated functionalized congener
ADAC (N6-[4-[[[4-[[[(2-aminoethyl)amino]carbonyl]methyl]anilino]carbonyl]methyl]phenyl]-
adenosine) achieved unanticipated high selectivity in binding to the cytoprotective human A3 AR, a
class A GPCR. The key to this selectivity of > 100-fold in both radioreceptor binding (Ki app = 2.4
nM) and functional assays (EC50 = 1.6 nM in inhibition of adenylate cyclase) was maintaining a free
amino group (secondary) in an amide-linked chain. Attachment of neutral amide-linked chains or
thiourea-containing chains preserved the moderate affinity and efficacy at the A1 AR subtype, but
there was no selectivity for the A3 AR. Since residual amino groups on dendrimers are associated
with cytotoxicity, the unreacted terminal positions of this A3 AR-selective G2.5 dendrimer were
present as carboxylate groups, which had the further benefit of increasing water-solubility. The A3
AR selective G2.5 dendrimer was also visualized binding the membrane of cells expressing the A3
receptor but did not bind cells that did not express the receptor.
Conclusion: This is the first example showing that it is feasible to modulate and even enhance the
pharmacological profile of a ligand of a GPCR based on conjugation to a nanocarrier and the precise
structure of the linking group, which was designed to interact with distal extracellular regions of
the 7 transmembrane-spanning receptor. This ligand tool can now be used in pharmacological
models of tissue rescue from ischemia and to probe the existence of A3 AR dimers.
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Background
Dendrimers bearing multiple ligands may have increased
avidity to a receptor compared to the monovalent ligand,
particularly if the ligand has a weak affinity for the recep-
tor [1]. While this phenomenon has only been loosely
demonstrated with PAMAM dendrimers, it is well estab-
lished that multivalent oligo- and poly-saccharides,
including PAMAM glycodendrimers, show some enhance-
ment in binding compared to the monovalent saccharide,
which is known as the cluster glycoside effect [2]. Den-
drimer-ligand complexes have also been used as imaging
agents [3] and for gene delivery [1]. Recently, we also
attached CGS21680, an A2A adenosine receptor (AR) ago-
nist, to G3 PAMAM dendrimers, providing the first exam-
ple of a GPCR ligand to be conjugated covalently to a
dendrimer while retaining its biological activity [4].
The ARs are GPCRs that have a generally cytoprotective
role and their ligands are of increasing therapeutic inter-
est. The A1 AR and A3 AR inhibit adenylyl cylase through
the coupling of the Gi protein and are also involved in
activating phospholipase C and potassium channels [5].
The A1 AR is highly expressed in the brain, spinal cord,
eye, and atria while intermediate expression is found in
the liver, kidney, and adipose tissue [6]. The A3 AR is
upregulated in peripheral blood mononuclear cells of
patients with rheumatoid arthritis as well as in several
breast, colon and pancreatic carcinoma tissues [7], but
more studies are needed to learn about the expression of
this protein in normal patients. Preconditioning of cardi-
omyocytes with either A1  or A3  AR agonists protects
against myocardial ischemia. This cardioprotection occurs
through extracellular signal-regulated kinase (ERK) sign-
aling and activation of the mitochondrial K+-ATP chan-
nels [5]. A1 AR agonists also inhibit lipolysis [6] and may
act as anti-epileptic agents [8], while A3 AR agonists may
protect against lung injury and cancer [9,10].
The AR ligands chosen for conjugation to both G2.5 or G3
PAMAM dendrimers in the present study are the A1 AR
agonist  N6-[4-[[[4-[[[(2-aminoethyl)amino]carbo-
nyl]methyl]anilino]-carbonyl]methyl]phenyl]adenosine
(ADAC, 1) and related functionalized congeners (Figure
1). Functionalized congeners are designed by adding a
chain substituent to a pharmacophore in a strategic, per-
missive location so that conjugation to other large mole-
Synthesis of novel functionalized congener monomers related to ADAC Figure 1
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cules is possible [11]. Ideally, the linker is modified to
enhance the interaction of the pharmacophore with the
receptor. This approach has been used to study A1 [12],
A2A [13], and A3 ARs [11]. ADAC is a highly selective A1 AR
agonist at the rat ARs and also displays some selectivity
towards the human A1 AR and human A3 AR in compari-
son to the human A2A AR [5,14]. ADAC protects against
neuronal damage and mortality after either acute or
chronic administration prior to a ten-min bilateral cere-
brovascular occlusion in gerbils. Significantly higher
doses of other A1 AR agonists are needed to produce an
equivalent effect [15]. ADAC also provides neuronal pro-
tection when given up to twelve hours post-ischemia [16].
Each of the dendrimer nucleoside conjugates also con-
tained a fluorescent moiety for in vitro and in vivo localiza-
tion.
Results
This study was designed to probe the feasibility of modu-
lating the potency and selectivity of nucleoside agonist lig-
ands of ARs based on conjugation to a PAMAM
nanocarrier.
Synthesis of ADAC-Related Functionalized Congeners and 
Dendrimer Conjugates
ADAC, an amine-derivatized nucleoside that potently
binds to and activates the A1 AR, was coupled covalently
to the surface of polyamidoamine (PAMAM) dendrimers
of generation 2.5 (G2.5). Two other linker moieties were
applied for comparison: one containing a secondary
amine and another containing an extended arylthiourea
group, which was attached to a G3 PAMAM dendrimer as
shown in Figure 1B. Two nucleoside intermediates related
to ADAC, 4 and 7, which had chains that could be cou-
pled to PAMAM dendrimers, were synthesized as shown
in Figure 1. 3-(p-Aminophenyl)propanoic acid 2 was con-
verted to 3-(p-isothiocyanatophenyl)propanoic acid 3 by
addition of thiophosgene in aqueous medium. The isothi-
ocyanate group of 3 was then conjugated to the terminal
amino group of ADAC to form a thiourea linkage in 4,
which had a terminal carboxyl group that could be cou-
pled to the amino group of the G3 PAMAM dendrimer. To
synthesize the diamino derivative 7, diethylenetriamine 6
was heated with methyl ester 5, which was similar to a pre-
vious method [17]. This product has a terminal primary
amine group that was coupled to the G2.5 PAMAM den-
drimer, with preference for its acylation over the second-
ary amine.
Each of the G3 and G2.5 dendrimer conjugates also con-
tained an AlexaFluor 488 (AF488) moiety [18] for fluores-
cent detection. G3-PAMAM-AF488-3 4  (12) and G3-
PAMAM-AF488-8 4 (13) were synthesized as shown in
Figure 2. First, the G3 dendrimer was partially acetylated
with acetic anhydride to decrease toxicity. Next, the Alexa-
Fluor 488 moiety was attached using either a PyBOP cou-
pling in the presence of triethylamine as base [4] or an
EDC coupling at pH 5 [19,20]. Finally, an amide bond
was formed between the carboxyl group of 2 and several
terminal amines on the G3 dendrimer using a PyBOP cou-
pling for 13 [4] and an EDC coupling for 12 [19,20].
Another goal was to compare 2.5 PAMAM – conjugates of
A1 AR agonists with G3 PAMAM – conjugates of similar
agonists. However, in order to attach AF488 to the carbox-
ylic G2.5 dendrimer, it was necessary to synthesize a new
Synthesis of compounds 12 and 13 – derivatives of G3 PAMAM dendrimer Figure 2
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AF488 derivative having a terminal primary amine. Initial
attempts were made to couple ethylenediamine to 10
using triethylamine in DMF or DMSO, but the AF488 did
not appear stable under these conditions. However, a var-
iation of the method using ethylenediamine in 0.1 M
NaB4O7, pH 8.5, was successful. After HPLC purification
and lyophilization, compound 14 was isolated in 93%
yield.
G2.5-PAMAM-AF488-1 (16) and G2.5-PAMAM-AF488-7
(17) were synthesized as shown in Figure 3. First, a carbo-
diimide coupling was used to attach the AF488 derivative
14 to the G2.5 dendrimer, using EDC in 0.1 M MES, pH 5
[19,20]. The unreacted EDC and urea byproduct were
removed by dialysis. Next, the terminal amino groups of
either 1 or 7 were amide conjugated to the G2.5 den-
drimer also using a carbodiimide coupling.
The conjugates were purified using size exclusion chroma-
tography and characterized using NMR and electrospray
ionization (ESI) mass spectrometry (MS) (see Additional
file 1). The parent G3 dendrimer matched its theoretical
weight, but the parent G2.5 dendrimer appeared to be
missing 2 propionate groups in the largest peak in the
mass spectrum, as shown in Figure S1 (Additional file 1).
Due to the excessive amount of sodium, the G2.5 spec-
trum was significantly more fragmented than the G3 spec-
trum. These spectra appear to be one of the first examples
of using ESI MS rather than MALDI MS to obtain data on
the PAMAM dendrimers.
After removal of the monomers by dialysis, NMR showed
that approximately three and eight molecules of 4 were
attached per dendrimer, on average, in derivatives 12 and
13, respectively. Interestingly, while the mass spectrum of
13 was very close to the theoretical mass, the mass spec-
trum of both compounds was very fragmented as shown
in Figure S2 (Additional file 1). The largest peak of 12
appeared to differ from the theoretical mass by approxi-
mately 1.8%, possibly due to the molecule breaking down
in the mass spectrometer. The majority of the amino
groups on the dendrimer appeared to be acylated, which
has previously been shown to significantly decrease toxic-
ity [21].
Synthesis of compounds 16 and 17 – derivatives of G2.5 PAMAM dendrimer Figure 3
Synthesis of compounds 16 and 17 – derivatives of G2.5 PAMAM dendrimer.
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NMR indicated that on average there were approximately
three nucleoside ligand moieties attached to each den-
drimer in purified derivatives 16 and 17. The mass spec-
trum of 16  was different from the theoretical mass by
approximately 1 nucleoside moiety, possibly due to the
compound decomposing in the mass spectrometer. The
mass spectrum of 17 was too fragmented to be useful as
shown in Figure S3 (Additional file 1). The largest peak in
the spectra was smaller than 15, the dendrimer with only
the AF488 moiety attached. However, smaller peaks in the
spectrum were closer to the theoretical weight. Unlike the
spectra for 13  and  14, there was significantly more
sodium in these spectra, which may have caused the diffi-
culties in obtaining these spectra. Also, the parent G2.5
dendrimer had more fragmentation than the parent G3
dendrimer. The difficulty in obtaining mass spectral data
for dendrimers is a known phenomenon [21].
Pharmacological Characterization of ADAC-Related 
Functionalized Congeners
The human AR binding affinity of these functionalized
congeners was measured prior to attachment to the den-
drimers (Table 1) [22]. Both 4 and 7, the new ADAC deriv-
atives, had slightly lower affinity than ADAC itself at the
A1 AR, with Ki app values of 30 nM and 43 nM, respectively.
While 4 retained selectivity similar to ADAC towards the
A1 AR in comparison to A2A AR, 7 was slightly less selec-
tive. Interestingly, 7 had a similar affinity for the A3AR as
ADAC, while 4  had significantly lower affinity at this
receptor. [35S]GTPγS binding, a functional assay for Gi
protein activation [23], was completed in membranes
expressing the A1 AR (Table 2). Compound 7, with an
EC50 value of 63 nM in activation of GTPγS binding via the
A1 AR, was 20-fold more potent than 4 and slightly more
potent than ADAC. In an assay measuring the inhibition
of the production of cAMP (Table 2), compound 7 was
also the most potent monomer at the A1 and A3 ARs. Com-
pound 7 was 3 – 7 fold more potent in adenylyl cyclase
assays at these two ARs than either ADAC or 4, which were
nearly equipotent at both the A1 and A3 ARs. All com-
pounds were shown to be full agonists at the A1 and A3
ARs in both assays.
Pharmacological Characterization of Nuceloside-
Dendrimer (G3) Conjugates
In the radioligand binding studies, the G3 dendrimer-lig-
and conjugates 12 and 13 had a comparable affinity to the
free monomer 4 at the A1 AR, but maintained a lower
degree of A1 selectivity compared to the A2A AR. However,
both conjugates had a higher affinity at the A3 AR than the
free monomer. The control dendrimer, 11, which con-
tained AF488 and multiple acetamide moieties but not
the nucleoside ligand, showed no binding at the A1 AR. At
the A2A and A3 ARs, weak binding inhibition was evident
at 10 μM, which might be a result of association of the
radioligand with the dendrimer conjugate at high concen-
trations. This phenomenon was seen in the A2A AR ago-
nist-dendrimer conjugates as well [24]. The control
dendrimer 11 also showed slight activity at 10 μM in the
stimulation of [35S]GTPγS binding. However, at 10 μM, 11
was unable to significantly inhibit cAMP production at
the A1 AR or the A3 AR. In an assay measuring [35S]GTYγS
binding at the A1 AR, the G3 dendrimer ligand conjugates
12 and 13 had EC50 values that were at least 4 fold lower
than the free monomer. Both of the dendrimer ligand
conjugates 12 and 13 were almost 5 – 10 fold more potent
at the A1 AR than the free monomer in an assay measuring
inhibition of cAMP production. Therefore, conjugating
the nucleoside 4 to the dendrimer improved the potency
in activation of the A1 AR even though the affinity was
similar in the radioligand binding.
Pharmacological Characterization of Nuceloside-
Dendrimer (G2.5) Conjugates
Radioligand binding was completed for each of the G2.5
dendrimer conjugates. Compound 17 showed a 2.4 nM
affinity for the A3 AR while compound 16 had a 14 nM
affinity for this receptor. Interestingly, 16  displayed at
least a 10-fold selectivity, and compound 17 displayed
over a 100 fold selectivity for the A3 AR in comparison to
the A1 and A2A ARs (Figure 4). Compound 17 was also 100
fold selective for the A3 AR in comparison to A1 AR in
assays of adenylate cylase inhibition with an EC50 value of
1.6 nM at the A3 AR (Figure 5). However, in this assay, 16
was only 8 fold more potent at the A3 AR than at the A1 AR.
In GTPγS studies, 16 was 15 fold less potent at the A1 AR
than in an assay measuring the suppression of cAMP pro-
duction; however, 17 had similar potency at both A1 AR
Table 1: Ki apparent values for binding of nucleoside monomers 
and dendrimer conjugates at A1, A2A, and A3 ARs.a
Compound A1 Ki (nM) A2A Ki (nM) A3 Ki (nM)
Nucleoside Monomers
1 10.4 ± 3.8 370 ± 100 12.2 ± 4.1
4d 30 ± 9 800 ± 360 74 ± 20
7d 43 ± 5 300 ± 20 9.5 ± 2.0
Dendrimer Derivatives
11 NBb (20 ± 7%)c (26 ± 3%)c
12 21 ± 5 250 ± 40 27 ± 2
13 55 ± 10 405 ± 170 42 ± 17
15 NBb NBb NBb
16 175 ± 60 610 ± 110 14.0 ± 2.1
17d 320 ± 20 470 ± 50 2.4 ± 0.4
a. All experiments were performed using adherent CHO cells stably 
expressing the A1 or A3 AR or HEK cells stably expressing A2A AR. 
Binding was carried out as described in methods using [3H]CCPA, 
[3H]CGS21680, or [125I]AB-MECA. Values are expressed as Ki values 
(mean ± SEM, n = 3) or as displacement of the radioligand at 10 μM. 
b. NB, No binding. Inhibition of radioligand binding < 10% at 10 μM. c. 
Percent inhibition of radioligand binding at 10 μM. d. 4, MRS5145; 7, 
MRS5169; 17, MRS5183.Journal of Nanobiotechnology 2008, 6:12 http://www.jnanobiotechnology.com/content/6/1/12
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functional assays, and both compounds were full agonists
in both assays. In the GTPγS study, DPCPX, an A1 antago-
nist, was able to fully inhibit the binding of [35S]GTPγS
when incubated with 17  (Figure 6), showing that the
binding is due to the specific interaction of 17 with the A1
receptor. The control dendrimer 15 showed no binding or
activity in either cAMP or GTPγS assays of A1 AR activa-
tion. The stably transfected CHO A1 and A3 cells had Bmax
values of 530 ± 210 fmol/mg protein and 253 ± 19 fmol/
mg protein, respectively, showing that there is similar
receptor expression in both cell lines.
Fluorescent Detection of Dendrimer (G2.5) Conjugates 
Bound to A3 AR Expressed in CHO Cells
10 μM of compounds 15 or 17 were incubated for 1 h
with CHO cells that did or did not stably express the A3
AR. After one wash with PBS, the cells were imaged at
100× magnification on a Zeiss AxioVision D1 Imager, and
both light and fluorescent pictures were obtained. As
shown in Figure 7, only the cells expressing the A3 AR were
bound by 17. Neither type of CHO cells were bound by
15, the control dendrimer with no ligand attached. 17 was
cAMP inhibition curves for 7 and 17 Figure 5
cAMP inhibition curves for 7 and 17. After 30 min incu-
bation with increasing concentrations of 7 or 17, forskolin 
was added to CHO cells expressing A1 or A3 ARs to increase 
adenylyl cylase. The inhibition of adenylyl cylase was meas-
ured using the Direct cAMP Enzyme Immunoassay. For a 
summary of EC50 values obtained, see Table 2. The results 
shown are means ± S.E.M. of three independent experi-
ments.
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Table 2: Functional EC50 values for nucleoside monomers and dendrimer conjugates to activate the A1 AR ([35S]GTPγS binding and 
cAMP inhibition) and A3 AR (cAMP inhibition).a
Compound A1 
([35S]GTPγS binding), EC50 (nM)
A1
(adenylyl cyclase), EC50 (nM)
A3
(adenylyl cyclase), EC50 (nM)
Nucleoside Monomers
1 94 ± 26 400 ± 80 100 ± 50
4 1300 ± 400 350 ± 20 140 ± 70
7 63 ± 14 89 ± 17 36 ± 13
Dendrimer Derivatives
11 50%b inactivec inactivec
12 190 ± 70 23 ± 10 25 ± 10
13 940 ± 70 54 ± 20 17 ± 2
15 < 10%b inactivec inactivec
16 2400 ± 1300 120 ± 1 14 ± 5
17 370 ± 190 260 ± 90 1.6 ± 0.4
a. All experiments were performed using adherent CHO cells stably expressing the A1 or A3 AR. Binding of [35S]GTPγS and assays using a cAMP kit 
were carried out as described in methods. Values are expressed as EC50 values (mean ± SEM, n = 3) or as displacement of the radioligand at 10 μM. 
b. Percent of [35S]GTPγS binding at 10 μM compared to full agonist. c. Compound produced less than 20% of total inhibition at 10 μM as seen by 
ADAC.
Radioligand binding curves for 17 Figure 4
Radioligand binding curves for 17. Increasing concentra-
tions of 17 were incubated with the appropriate radioligand 
(A1: [3H]CCPA, A2A: [3H]CGS21680, A3: [125I]I-AB-MECA) 
and a suspension of CHO cell membranes (A1 or A3) or HEK 
cells (A2A) expressing the appropriate receptor. For a sum-
mary of Ki values obtained, see Table 1.
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unable to bind CHO cells that did not express the A3 AR.
While background fluorescence was seen for both com-
pounds 15 and 17 when incubated with the CHO cells,
this fluorescence did not correspond to the location of the
cells. The fluorescence bound to the surface of the A3AR-
expressing cells was not evenly distributed, but rather
showed a punctuated distribution, possibly due to recep-
tor aggregation.
Discussion
Many drugs have already been delivered using dendrimers
by bioreversible covalent conjugation, including meth-
otrexate [25] and penicillin V [26]. Methotrexate, which
was covalently attached via a hydrolyzable ester bond to a
generation 5 (G5) PAMAM dendrimer that also contained
folic acid, was significantly more toxic to folic acid recep-
tor-expressing cancer cells than was the free ligand. The
dendrimer with the ligand and folic acid attached and
monomeric folic acid appeared to have a similar affinity
for the folic acid receptor [25]. Our study differs from the
bioreversible approach in that it describes covalent nucle-
oside-dendrimer conjugates that do not require cleavage
in order to achieve a biological effect. It extends previous
studies in which another receptor subtype, the A2A AR, was
targeted [4,24].
The previous studies of A2A AR-directed dendrimers uti-
lized exclusively amino-terminal dendrimers, such as G3
PAMAM dendrimers. Dendrimers with free amino groups
at the periphery typically display a toxicity that is depend-
ent on both size (i.e. generation) and concentration. This
toxicity can be ameliorated by using neutral or anionic
dendrimers, such as half-generation PAMAM dendrimers
that have terminal carboxyl groups [21]. For instance, G3
PAMAM dendrimers caused significant haemolysis at 4
mg/ml in red blood cells, whereas G2.5 PAMAM did not
cause haemolysis at 10 mg/ml [27]. In fact, only G7.5
PAMAM and higher generations caused significant
haemolysis at 4 mg/ml. Therefore, we have included in
this study dendrimers of half-generation, e.g. 2.5, which
have terminal carboxylate groups and are therefore likely
to be less toxic. When the G3 dendrimer was used in the
present study, most of the amino groups were blocked to
avoid cytotoxicity.
The differences between half-generation compared to
integral generation PAMAM dendrimers in drug delivery
have not been adequately studied. One study did attach
methotrexate to G2.5 and G3 dendrimers using the termi-
nal amine and carboxyl groups of the ligand, respectively,
and the G2.5 conjugate had increased drug activity com-
pared to either free methotrexate or the G3 conjugate [28].
However, the major reason given for the increased activity
with the G2.5 derivative was that the methotrexate was
released from the dendrimer due to prolonged interac-
tions with proteases in the lysosome since the G2.5 deriv-
ative has an anionic charge. The paper concluded that it
was probably necessary for the drug to be released from
the dendrimer in order to retain its cytotoxic activity.
However, GPCR ligands activate their receptors from out-
side of the cell, and it is unlikely that the ligand will need
to be released from the dendrimer to retain activity. There-
fore, there must be a different explanation for the
improvement of selectivity and affinity of the G2.5 den-
drimer-ligand conjugates.
The two functionalized congeners related to ADAC as well
as ADAC itself were attached to the dendrimer through a
terminal side chain attached to the same position on the
nucleoside and which should not interfere with the bind-
ing of the adenosine moiety to the receptor. Each of the
nucleoside monomers (compounds 1, 4, and 7) showed
less than a 5 fold difference in affinity between the human
A1 and A3 ARs, but 17 had an enhanced affinity and selec-
tivity at A3 AR in both radioligand binding and cAMP
assays. This enhancement can be explained by the differ-
ence in the linking moieties, such that the G2.5 den-
drimer-ligand conjugates 16 and 17 allow a significant
increase in selectivity towards the A3 AR compared to the
A1 AR. This selectivity was not seen with the G3 den-
drimer-ligand conjugates, which were approximately
equipotent at the A1 and A3 ARs in both radioligand bind-
ing and cAMP assays. However, the decrease in affinity at
the A1 AR and increase in affinity at A3 AR was seen in our
previous work using A2A AR-directed G3 dendrimer-ligand
conjugates. This work showed that dendrimer-nucleoside
conjugates increased the selectivity at the A2A AR com-
Antagonism by an A1AR antagonist of [35S]GTPγS binding  induced by compound 17 Figure 6
Antagonism by an A1AR antagonist of [35S]GTPγS 
binding induced by compound 17. Compound 17 was 
incubated with increasing concentrations of A1 antagonist 
DPCPX, [35S]GTPγS, and a CHO A1 membrane suspension. 
The amount of [35S]GTPγS bound was measured, and the 
results were interpreted with Prism software. The results 
shown are means ± S.E.M. of three independent experi-
ments.
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pared to the A1 AR by decreasing the binding affinity at the
A1 receptor, and that all of the dendrimer ligand-conju-
gates were most potent at the A3 AR [24]. Dendrimer-con-
jugates 12 and 13, which are approximately equipotent at
A1 and A3 ARs could be useful for cardioprotection [29],
while A3 AR selective conjugates 16 and 17 could be useful
in the treatment of rheumatoid arthritis [30].
Since residual amino groups on dendrimers are associated
with cytotoxicity, the unreacted terminal positions of the
A3 AR-selective G2.5 dendrimer 17 were present as carbox-
ylate groups, which had the further benefit of increasing
water-solubility. Interestingly, not only does the A3 AR
selectivity of 17 improve upon conjugation to the den-
drimer, but the affinity also slightly improves compared
to the parent nucleoside, 7. While this could be due to the
fact that the nucleoside concentration is higher since there
are multiple ligands attached per dendrimer, it is unlikely
that this is the sole cause of the phenomenon. There are
only on average three ligands attached per dendrimer, so
it is unlikely that all of them are in the correct geometry to
bind multiple receptor proteins in the membrane simulta-
Light and fluorescent microscopy of CHO or CHO A3 cells with compound 17 Figure 7
Light and fluorescent microscopy of CHO or CHO A3 cells with compound 17. The cells were plated 24 h prior to 
the experiment. The cells were incubated for 1 h with the 10 μM of the appropriate compound and imaged with light and fluo-
rescent microscopy. A. CHO A3 cells, fluorescent image; B. CHO A3 cells, light image; C. CHO cells, fluorescent image; D. 
CHO cells, light image.
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neously. It is possible that the dendrimer-ligand conjugate
would be blocking other receptor binding sites for the
radioligand since it is much larger than the monomer.
However, if this was the case, it would be expected that
each of the dendrimer-ligand conjugates is more potent
than the free nucleosides; instead, the conjugate 16  is
approximately equipotent to 1. It could also be possible
that due to the overexpression of the A3 AR on the CHO
cells, A3 AR dimers are forming and the dendrimer conju-
gate is able to bridge the binding sites of both receptors.
A3 ARs are known to accumulate in membrane microdo-
mains and may form A3 AR homodimers [31]. If there is
only one G protein associated with the GPCR dimer, the
receptor that is not attached to the G protein could act as
an anchor for the dendrimer ligand complex, allowing for
a lowering of the EC50 and Ki app values. Previously molec-
ular modeling work at the A2A AR has shown that one den-
drimer with multiple ligands could bridge an AR dimer
[32]. However, further studies are necessary to elucidate
the mechanism for the improvement of selectivity and
potency of 17 in comparison to 7.
Compound 17 was also studied using fluorescent micros-
copy. Interestingly, 17, but not 15, the control dendrimer
with no ligand attached, was able to bind CHO cells
expressing the A3  AR. Neither compound significantly
bound to cells that were not expressing the A3 AR. The flu-
orescence remained associated with the cells expressing
the A3 AR after washing. Compound 17 appeared to bind
some areas of the membrane more strongly than other
areas as shown by increase in fluorescent signal. This find-
ing could provide evidence that the A3 AR is condensed
into patches on the cell membrane, possibly as dimers or
oligomers. The uneven distribution of the fluorescent sig-
nal might indicate the existence of higher-order receptor
oligomers, as it been recently demonstrated for the A2A AR
[33]. We did not use transmission electron microscopy to
determine if the fluorescent dendrimer conjugate was
internalized by the cells. Internalization of other GPCRs
under similar conditions, i.e., incubation with agonist for
1 hr at 37°C, is established. These two issues might be
responsible of the punctuate distribution of A3  AR-
dependent binding of 17.
Compounds 12 and 13 are identical, except that 13 con-
tains an additional five ADAC moieties per dendrimer.
Interestingly, attaching additional ADAC moieties to G3
PAMAM appeared to cause a slight decrease in affinity at
all three ARs, although the selectivity remained similar.
Our previous results comparing increasing numbers of
A2A AR ligand attachments to dendrimers also failed to
show a significant improvement in affinity by adding
multiple ligands to the dendrimer [24]. However, in both
of these studies, attaching the monomer to the dendrimer
did not create a significant enhancement in affinity,
unlike in our new G2.5 conjugates. Therefore, it will be
interesting to determine if there is an enhancement in
affinity when increasing numbers of ADAC moieties are
attached to the G2.5 dendrimers.
Conclusion
In conclusion, it is feasible to modulate and even enhance
the pharmacological profile of a ligand of a GPCR based
on conjugation to a nanocarrier and the precise structure
of the linking group, which was designed to interact with
distal extracellular regions of a 7 transmembrane-span-
ning receptor. We have demonstrated the feasibility of
potent and selective activation of specific subtypes of ARs
using multivalent conjugates and the ability to modulate
the selectivity based on the linkage between the pharma-
cophore and the polymeric carrier. Both G2.5 and G3
PAMAM dendrimers can be successfully used in covalent
dendrimer-ligand conjugates directed to GPCRs. High
selectivity in binding at the A3 AR in comparison to the
monomeric nucleosides could be achieved, depending on
the nature of the linker moiety, i.e., a secondary amine
linkage resulted in greater than 100-fold A3 AR selectivity.
The selective macromolecular agonist 17 can now be used
in pharmacological models of tissue rescue from ischemia
and as a fluorescent ligand tool to characterize the A3 AR
in situ and to probe the existence of A3 AR dimers. Further
studies will be completed using higher generation den-
drimers and with new covalently-bound AR ligands.
Other GPCRs may also be amenable to this approach to
the design of multivalent ligands.
Methods
Materials
ADAC, PAMAM dendrimers (ethylenediamine core, gen-
erations 2.5 as 10 wt. % solution in methanol and gener-
ations 3 as 20 wt. % solution in methanol solution), 3-(4-
aminophenyl)propionic acid, (benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophos-phate
(PyBOP), 3-[(3-cholamidopropyl)dimethyl-ammonio]-
1-propanesulfonate hydrate (CHAPS), adenosine deami-
nase, bovine serum albumin, sodium borate, guanosine
5'-diphosphate sodium salt (GDP), N-(3-dimethylamino-
propyl)-N'-ethylcarbodiimide (EDC), dithiothreitol, eth-
ylene-diaminetetraacetic acid acetic anhydride (EDTA), 2-
(N-morpholino)ethanesulfonic acid (MES), magnesium
chloride, sodium chloride, methanol, thiophosgene, tri-
ethylamine, diethyl ether, methyl sulfoxide-d6 (DMSO-
d6), and N, N-dimethylformamide (DMF) were purchased
from Sigma (St. Louis, MO). Bio-Beads® SX-1 beads were
purchased from Bio-Rad (Hercules, CA). Alexa-Fluor® 488
carboxylic acid, 2,3,5,6-tetrafluorophenyl ester, 5-isomer
(AF488-TFP) was purchased from Invitrogen (Carlsbad,
CA). [125I]-4-Amino-3-iodobenzyl-5'-N-methylcarboxam-
idoadenosine ([125I]AB-MECA, 2200 Ci/mmol), [3H]-2-
chloro-N6-cyclopentyladenosine ([3H]CCPA, 42.6 Ci/Journal of Nanobiotechnology 2008, 6:12 http://www.jnanobiotechnology.com/content/6/1/12
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mmol), and [3H]-2-[p-(2-carboxyethyl)phenylethyl-
amino]-5'-N-ethylcarboxamidoadenosine
([3H]CGS21680, 40.5 Ci/mmol) were purchased from
Perkin Elmer (Waltham, MA). [35S]GTPγS (1133 Ci/
mmol) was purchased from GE Healthcare (Buckingham-
shire, England). DMEM/F12 medium and 1 M Tris-HCl
(pH 7.5) were purchased from Mediatech, Inc. (Herndon,
VA).
Chromatography and spectroscopy
To prepare a column for size exclusion chromatography
(SEC), 100 g of Bio-Beads® SX-1 beads were suspended in
1 L of DMF. After 24 h to allow for equilibration and
expansion, the beads were added to the column as
described previously [21]. High Performance Liquid
Chromatography (HPLC) purification was performed
using an Agilent 1100 Series HPLC (Santa Clara, CA)
equipped with a Phenomenex Luna 5μ C18(2) 100A ana-
lytical column (250 × 10 mm; Torrance, CA). Peaks were
detected by UV absorption using a diode array detector.
Proton nuclear magnetic resonance spectra (NMR) were
recorded on a Bruker DRX-600 spectrometer after being
optimized for each sample using DMSO-d6 as a solvent
unless otherwise noted. To determine the number of lig-
ands attached to each dendrimer, the integration of NMR
resonances of the ligand was compared to the integration
of signal from one of the sets of carbon-protons on the
interior of the dendrimer as described previously [4]. Elec-
trospray ionization mass spectra (ESI MS) were taken
using a Waters LCT Premier mass spectrometer. Matrix
Assisted Laser Desorption/Ionization Time-of-Flight
(MALDI-TOF) spectra were obtained with a Waters Micro
mass spectrometer using Waters MassPREP Direct Ioniza-
tion on Silica Desorption/ionization (DIOS) target plates.
The ESI MS data for the dendrimer complexes was
obtained using a Waters LCT Premier TOF mass spectrom-
eter. The mass spectrometer was operated in positive ion
W mode with a resolution of 10000 measured at half peak
height. The capillary voltage was 2500 volts, the cone volt-
age was 40 volts, and the desolvation gas was dried nitro-
gen at 250°C and a flow of 300 L/h. The sample was
dissolved in a 1:1 solution of water:acetonitrile contain-
ing 0.2% formic acid and injected directly into the eluting
stream flowing at 200 μL/min and consisting of 20:80
water:acetonitrile and 0.2% formic acid. The relevant
spectra were summed using the MassLynx software, and
the summed spectrum was deconvoluted with the Max-
EntI program.
Chemical synthesis – 3-(4-Thiocarbamoylphenyl)propanoic acid (3)
3-(4-Aminophenyl)propanoic acid (2) (100 mg, 670
μmol) was dissolved in 0.7 mL of 0.8 M aqueous KOH.
Thiophosgene (51.1 μL, 670 μmol) was diluted with 1.2
mL of water. The 3-(4-aminophenyl)propanoic acid solu-
tion was added dropwise to the freshly prepared thio-
phosgene solution. A solid immediately precipitated and
redissolved upon the addition of 4.2 mL water. After 1 h,
the solution was vacuum-filtered and vacuum-dried over-
night to give 98.6 mg of 3-(4-thiocarbamoylphenyl)pro-
panoic acid (475 μmol, 80% yield). 1H NMR (CDCl3)
7.27–7.30 (m, 2 H), 7.15–7.23 (m, 2 H), 2.93 (t, J = 7.9
Hz, 2 H), 2.68 (t, J = 7.4 Hz, 2H) m/z (M+ ESI MS) calc:
208.0432 found: 208.0423.
3-(4-(3-(2-(2-(4-(2-(4-(9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-
ylamino)phenyl)acetamido)-
phenyl)acetamido)ethyl)thioureido)phenyl)pro-panoic acid (4)
3-(4-Thiocarbamoylphenyl)propanoic acid (3) (12 mg,
60.7 μmol) and ADAC (1) (35 mg, 60.7 μmol) were dis-
solved in 4 ml of DMF. Triethylamine (20 μL, 143 μmol)
was added, and the reaction was stirred for 1 h. The DMF
was removed under nitrogen and the resulting oil was dis-
solved in methanol. Ether was added to precipitate the
product. After removal of the supernatant and drying, the
resulting product (17.8 mg, 22.8 μmol, 37% yield) was
judged homogenous by TLC. 1H NMR (DMSO-d6) 10.10
(s, 1H), 9.93 (s, 1H), 9.52 (br s, 1H), 8.53 (s, 1H), 8.37 (s,
1H), 8.10 (t, J = 6.1 Hz, 1H), 7.85 (d, J = 8.9 Hz, 2H), 7.66
(br s, 1H), 7.52 (d, J = 8.5, 2H), 7.21–7.33 (m, 4H),
7.13–7.20 (m, 4H), 5.95 (d, J = 6.0 Hz, 1H), 5.48 (d, J =
5.5, 1H), 5.29 (t, J = 5.6 Hz, 1H), 5.21 (d, J = 4.6 Hz, 1H),
4.63 (m, 1H), 4.17 (m, 1H), 3.98 (dd, J = 3.6, 4.0 Hz, 1H),
3.65–3.74 (m, 1H), 3.59 (s, 1H), 3.53 (m, 2H), 3.20–3.29
(m, 2H), 2.72–2.83 (m, 2H) m/z  (M+  ESI MS) calc:
784.2877 found: 784.2882.
N-(2-(2-Aminoethylamino)ethyl)-2-(4-(2-(4-(9-((2R,3R,4S,5R)-3,4-
dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-9H-purin-6-
ylamino)-phenyl)acetamido)phenyl)acetamide (7)
This compound was synthesized according to a similar
procedure to obtain ADAC (17).N6-[4-[[[4-((2-methoxy)-
2-oxyethyl)anilino]carbonyl]-methyl]-phenyl]adenosine
(5) (4.97 mg, 9.1 μmol) was dissolved in 1 mL of DMF,
and diethylenetriamine (6) (150 μL, 1.37 mmol) was
added to this solution. The reaction was stirred overnight
under nitrogen, and the DMF was removed under a stream
of dry nitrogen. The resulting oil was dissolved in metha-
nol, and a solid was precipitated upon addition of ether.
After removal of the supernatant, the remaining solid was
dried overnight to give 3.75 mg of product (6.05 μmol,
66.5% yield). 1H NMR (DMSO-d6) 10.11 (s, 1H), 9.94 (br
s, 1H) 8.53 (s, 1H), 8.38 (s, 1H), 7.90–8.04 (m, 2H), 7.84
(d, J = 9.0 Hz, 2H), 7.51 (d, J = 7.6 Hz, 2H), 7.29 (d, J =
8.4 Hz, 2H), 7.18 (d, J = 8.8 Hz, 2H), 5.95 (d, J = 6.9 Hz,
1H) 5.32 (m, 1H), 4.63 (t, J = 5.7 Hz, 1H), 4.17 (t, J = 4.8
Hz, 1H), 3.98 (dd, J = 3.4 Hz, 2.1Hz, 1H), 3.59 (m, 3H),
3.10–3.15 (m, 4H), 2.62 (m, 2H), 2.55 (s, 6H, 21, 22),Journal of Nanobiotechnology 2008, 6:12 http://www.jnanobiotechnology.com/content/6/1/12
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1.10 p (t, J = 6.8 Hz, 3H). m/z (M+ ESI MS) calc: 620.2945
found: 620.2931.
2-(6-Amino-3-iminio-4,5-disulfonato-3H-xanthen-9-yl)-5-(2-
aminoethylcarbamoyl)benzoate (14)
5 mg of AF488-TFP (10) (5.65 μmol) was dissolved in 280
μL of DMF. In order to provide a basic environment, 1.50
mL of 0.1 M NaB4O7, pH 8.5 was added. 10 μL of ethylen-
ediamine diluted with 210 μL of water was added, and the
mixture was stirred overnight. The product was purified
by HPLC using the following water/acetonitrile linear gra-
dient: 0 min, 0% acetonitrile; 25 min, 100% acetonitrile.
The product eluted at 10.8 min. After lyophilization, 3.02
mg of product (5.2 μmol) remained (93% yield). 1H NMR
(D2O) 8.33 (d, J = 2.3 Hz, 1H), 8.17 (t, J = 1.9 Hz, 1H),
7.90 (m, 1H), 7.24 (t, J = 7.5, 1H), 7.16 (dd, J = 7.5, 1.9,
1H), 7.08 (d, J = 9.6, 2H), 6.83 (t, J = 8.8, 4H), 3.63 (m,
1H), 3.51 (t, J = 11.7, 2H), 3.40 (t, J = 5.0, 2H), 3.13–3.21
(m, 2H)m/z  (M-  Na MALDI-TOF MS) calc: 597.0362
found: 597.0383.
G3 PAMAM – 23 Ac – AF488 (11) – Method 1
1 mL of G3 PAMAM methanol stock solution (18.8 mM,
18.8 μmol, Sigma) was added to a flask, and the methanol
was evaporated. The remaining polymer was dissolved in
1 mL of DMSO-d6. Acetic anhydride (40.8 μL, 432 μmol,
23 eq) was diluted in 1 mL of DMSO-d6, and this solution
was added dropwise to the solution of G3 PAMAM while
stirring. After 18 h, an NMR spectrum showed approxi-
mately 23 acetamide groups per dendrimer, as expected,
to give 9. 460 μl of this solution (4.32 μmol, 9.4 mM) was
removed and diluted to 1.46 mL with DMSO-d6. Triethyl-
amine (10 μL, 72 μmol) was added under a nitrogen
atmosphere. AF488-TFP (10) (4 mg, 4.52 μmol, 1.05 eq)
was dissolved in 400 μL of DMSO-d6 and added to the
mixture. After 48 h, the solution was vacuum filtered to
remove a small amount orange precipitate that formed.
The NMR spectrum was consistent with the assigned struc-
ture, but the signals resulting from AF488 could not be
properly integrated due to the large G3 PAMAM peaks.
The molecular weight of the compound was unable to be
determined using either ESI or MALDI-TOF MS. There-
fore, it was assumed that approximately one Alexa-Fluor
488 moiety was attached per G3 PAMAM, based on previ-
ous data [4].
G3 PAMAM – 23 Ac – AF488 (11) – Method 2
0.5 mL of G3 PAMAM methanol stock solution (18.8 mM,
9.4 μmol) was added to a flask, and the methanol was
evaporated. The remaining polymer was dissolved in 0.5
mL of DMSO-d6. Acetic anhydride (20.4 μL, 216 μmol, 23
eq) was diluted in 0.5 mL of DMSO-d6, and this solution
was added dropwise to the solution of G3 PAMAM with
stirring. After 18 h, an NMR spectrum of the reaction mix-
ture showed approximately 23 acetamide groups per den-
drimer, as expected, to give 9. 234 μL of this solution (2.2
μmol, 9.4 mM) was removed and diluted to 500 μL with
DMSO-d6. AF488-TFP (10) (2 mg, 2.3 μmol, 1.05 eq) was
dissolved in 300 μL of 0.1 M MES, pH 5 and added to the
mixture under nitrogen atmosphere. EDC (42 mg, 220
μmol) was dissolved in 300 μL of 0.1 M MES, pH 5 and
added to the reaction mixture. After 48 h, the solution was
vacuum filtered to remove a small amount orange precip-
itate that formed. The NMR spectrum was consistent with
the assigned structure, but the signals resulting from
AF488 could not be properly integrated due to the large
G3 PAMAM peaks. The molecular weight of the com-
pound was unable to be determined using either ESI or
MALDI-TOF MS. Therefore, it was assumed that approxi-
mately one Alexa-Fluor 488 moiety was attached per G3
PAMAM based on previous data [4].
G3 PAMAM – 23 Ac – AF488 (containing 3 moieties of 4) (12)
650 μL of 11 prepared by method 2 (2.0 mM solution in
DMSO-d6, 1.3 μmol) was removed and placed under
nitrogen gas. Compound 4 (5 mg, 6.4 μmol) was dis-
solved in 600 μL of DMSO and added to the mixture
under a nitrogen atmosphere. EDC-HCl (25 mg, 130
μmol) was dissolved in 350 μL 0.1 M MES, pH 5 and
added to the mixture. After 48 hr, the product was purified
by extensive dialysis (Specta/Por Membrane, MWCO
3500, flat width 18 mm, Spectrum Laboratories, Inc., Ran-
cho Dominguez, CA) in water. After lyophilization, 5.85
mg remained, which contained on average 3 moieties of 4
per dendrimer (0.54 μmol, 41% yield based on μmol of
dendrimer). 10.11 (s, 4H), 9.94 (s, 3H), 8.54 (s, 4H), 8.38
(s, 4H), 8.00 (s, 45H), 7.92 (s, 41H), 7.85 (s, 13H), 7.51
(br s, 6H), 7.29 (d, J = 7.5, 9H), 7.17 (m, 6H), 5.96 (d, J =
6.1, 2H), 5.49 (d, J = 4.2, 2H), 5.30 (t, J = 4.8, 2H), 5.22
(m, 3H), 4.63 (m, 3H), 4.18 (m, 3H), 3.98 (m, 3H), 3.33
(s, 226H), 3.08 (s, 203H), 2.70 (s, 124H), 2.23 (s, 120H),
1.80 (s, 69H). m/z (M+ ESI MS) calc: 10865 found: 11068.
G3 PAMAM – Ac – AF488 AF488 (containing 8 moieties of 4) (13)
660 μL of 11 prepared by method 1 (2.3 mM solution in
DMSO-d6, 1.52 μmol) was removed and placed under
nitrogen gas. Compound 4 (11.8 mg, 15 μmol) was dis-
solved in 200 μl of DMSO and added to the mixture.
Finally, a mixture of triethylamine (28 μL, 202 μmol) and
PyBOP (26 mg, 50 μmol) dissolved in 1.5 mL of DMSO
was added. After 48 hr, the product was purified by SEC
using DMF as the eluent. The fractions containing product
which had the Alexa-488 moiety were dried and dissolved
in DMSO-d6 for NMR. The first and last fractions contain-
ing the product were excluded to provide a more homog-
enous sample. The remaining fractions were combined
and dried to give 8.68 mg of product, which contained on
average 8 moieties of 4 per dendrimer (0.694 μmol, 46%
yield based on μmol of dendrimer). 1H NMR (DMSO-d6)
10.11 (s, 8H), 9.94 (s, 8H), 9.53 (s, 5H), 8.54 (s, 8H),Journal of Nanobiotechnology 2008, 6:12 http://www.jnanobiotechnology.com/content/6/1/12
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8.38 (s, 8H), 8.10 (t, J = 6.0 Hz), 7.96 (s, 41H), 7.90 (s,
33H), 7.84 (m, 41H), 7.52 (d, J = 8.6 Hz, 16H), 7.24 (d, J
= 8.3 Hz, 16H), 7.17 (m, 34H), 5.96 (d, J = 6.2, 7H), 5.50
(br s, 4H), 5.31 (br s, 7H), 5.22 (br s, 5H), 4.64 (t, J = 4.2
Hz, 8H), 4.18 (t, J = 3.4 Hz, 8H), 3.99 (dd, J = 2.7, 3.7,
8H), 3.70 (m, 11H), 3.59 (m, 44H), 3.08 (s, 176H), 2.90
(s, 8H), 2.74 (s, 9H), 2.65 (s, 120H), 2.43 (s, 77H), 2.19
(s, 120H), 1.80 (s, 69H). m/z (M+ ESI MS) calc: 14241
found: 14226.
G2.5 PAMAM – AF488 (15)
This procedure was adapted from a carbodiimide cou-
pling described previously [19,20]. 5 μmol of G2.5
PAMAM stock solution (14.3 mM in methanol, 31.3 mg)
was added to a flask, and the methanol was evaporated.
The remaining residue containing the polymer and com-
pound 14 (3.0 mg, 5.2 μmol) were dissolved in 1.7 mL of
0.1 M MES buffer, pH 5. EDC (40.4 g, 260 μmol) dis-
solved in 1 mL of 0.1 M MES buffer, pH 5, was added, and
the reaction stirred for 60 h. After dialysis with water, the
mixture was lyophilized to give 13.4 mg (1.97 μmol, 37%
yield) and redissolved in D2O for NMR measurements
and further biological assays. 1H NMR (D2O) 8.25 (s,
1H), 7.78–8.10 (m, 1H), 7.53 (s, 1H), 7.32 (s, 1H), 7.10
(s, 1H), 6.89 (m, 1H), 3.42 (s, 26H), 3.15 (m, 90H), 2.72
(s, 120H), 2.52 (s, 60H), 2.38 (m, 122H). The molecular
weight was unable to be determined using ESI or MALDI-
TOF MS due to stacking of the PAMAM dendrimer.
G2.5 PAMAM – AF488 (containing 3 moieties of 1) (16)
620 μL of a stock solution of 15 in D2O was dried to give
9.32 mg (1.4 μmol), which was redissolved in 1 mL of 0.1
M MES, pH 5 and placed under a nitrogen atmosphere
[20]. ADAC (8.92 mg, 14 μmol) was dissolved in 600 μL
of DMSO and was added to the solution of 15. Finally, 27
mg of EDC (141 μmol) was dissolved in 500 μL of 0.1 M
MES, pH 5 and added to the mixture. After approximately
48 h, small molecule impurities were removed by exten-
sive dialysis in water. After lyophilization, 8.06 mg (0.96
μmol, 68% yield) of product remained. The product was
analyzed by NMR, which showed approximately 3 ADAC
moieties attached per dendrimer. 1H NMR (DMSO-d6)
8.48 (s, 3H), 8.35 (s, 3H), 7.76 (s, 6H), 7.47 (m, 6H),
7.29 (m, 6H), 7.16 (m 6H), 5.92 (d, J = 5.5, 3H), 4.60 (m,
3H), 4.16 (m, 3H), 3.99 (m, 3H), 3.56 (s, 31H), 3.07 (s,
90H), 2.63 (s, 120H), 2.44 (s, 70 H), 2.20 (s, 120H). m/z
(M+ ESI MS) calc: 8405 found: 7811
G2.5 PAMAM – AF488 (containing 3 moieties of 7)(17)
640 μL of a stock solution of 15 in D2O was dried to give
10.2 mg (1.5 μmol), which was redissolved in 600 μL of
0.1 M MES, pH 5 and placed under a nitrogen atmos-
phere. 7 (9.2 mg, 15 μmol) was dissolved in 1 mL of
DMSO and was added to 15. Finally, 28 mg of EDC (146
μmol) was dissolved in 500 μL of 0.1 M MES, pH 5 and
added to the mixture. After approximately 48 h, small
molecule impurities were removed by extensive dialysis in
water. After lyophilization, 9.74 mg (1.14 μmol, 76%
yield) of product remained. The product was analyzed by
NMR, which showed approximately 3 ADAC moieties
attached per dendrimer. 1H NMR (DMSO-d6) 10.20 (s,
2H), 9.86 (s, 2H), 8.47 (s, 2H), 8.35 (s, 2H), 7.78 – 8.30
(m, 91H), 7.76 (br s, 7H), 7.47 (br s, 6H), 7.29 (br s, 5H),
7.16 (br s, 6H), 5.92 (t, J = 5.7, 2H), 5.30 (m, 6H), 4.60
(m, 5H), 3.54 (s, 46H), 3.10 (s, 104H), 2.98 (m, 28H),
2.63 (s, 160H), 2.42 (s, 78 H), 2.36 (s, 56H), 2.20 (s,
120H). The mass spectrum of this compound was too
fragmented to determine a molecular weight.
Cell Culture and Membrane Preparation
CHO (Chinese hamster ovary) cells stably expressing the
recombinant human ARs were cultured in Dulbecco's
modified Eagle medium (DMEM) and F12 (1:1) supple-
mented with 10% fetal bovine serum, 100 units/mL pen-
icillin, 100 μg/mL streptomycin, and 2 μmol/mL
glutamine. After harvesting, cells were homogenized and
suspended. Cells were then centrifuged at 500 g for 10
min, and the pellet was resuspended in 50 mM Tris-HCl
buffer (pH 7.5) containing 10 mM MgCl2. The suspension
was homogenized and was then recentrifuged at 20 000 g
for 20 min at 4°C. The resultant pellets were resuspended
in Tris buffer, incubated with adenosine deaminase for 30
min at 37°C, and the suspension was stored at -80°C
until the binding experiments. The protein concentration
was measured using the BCA Protein Assay Kit from Pierce
[20].
Radioligand Membrane Binding Studies
Radioligand binding assays were performed for A1 and A2A
ARs, following the procedure described previously [22].
Each tube in the binding assay contained 100 μL of mem-
brane suspension (20 μg of protein), 50 μL of agonist
radioligand, and 50 μL of increasing concentrations of the
test ligands in Tris-HCl buffer (50 mM, pH 7.5) contain-
ing 10 mM MgCl2. The concentration of the dendrimer-
ligand complexes are measured by the concentration of
the dendrimer, not the ligand. Therefore, all Ki values are
measured as Ki app values. Nonspecific binding was deter-
mined using a final concentration of 10 μM 5'-N-ethylcar-
boxamidoadenosine diluted with the buffer. The mixtures
were incubated at 25°C for 60 min. Binding reactions
were terminated by filtration through Whatman GF/B fil-
ters under a reduced pressure using a MT-24 cell harvester
(Brandell, Gaithersburg, MD). Filters were washed three
times with 5 mL of 50 mM ice-cold Tris-HCl buffer (pH
7.5). The radioactive agonists [3H]2-chloro-N6-
cyclopentyladenosine and [3H]2-(4-(2-carboxyethyl)phe-
nylethylamino)-5'-N-ethylcarboxamido-adenosine were
used for the A1 and A2A assays, respectively. All of the fil-
ters were washed 3 times with Tris-HCl, pH 7.5. Filters forJournal of Nanobiotechnology 2008, 6:12 http://www.jnanobiotechnology.com/content/6/1/12
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A1 and A2A AR binding were placed in scintillation vials
containing 5 mL of Hydrofluor scintillation buffer and
counted using a Perkin Elmer Liquid Scintillation Ana-
lyzer. Filters for A3 AR binding were counted using a Pack-
ard Cobra II γ-counter. The Ki values were determined
using GraphPad Prism for all assays.
cAMP Assays
CHO cells expressing either the A1 or A3 AR were seeded in
24 well plates and incubated at 37°C overnight. The fol-
lowing day the medium was removed and replaced with
DMEM containing 50 mM HEPES, 10 μM rolipram, 3 U/
ml adenosine deaminase and increasing concentrations of
the compounds. After a 30 min incubation at 37°C, 10
μM of forskolin was added to stimulate cAMP levels, and
the cells were incubated at 37°C for an additional 15 min.
The medium was removed, and the cells were lysed with
200 μl of 0.1 M HCl. 100 μl of the HCl solution was used
in the Sigma Direct cAMP Enzyme Immunoassay follow-
ing the instructions provided with the kit. The results were
interpreted using a Bio-Tek Instruments ELx808 Ultra
Microplate reader at 405 nm.
[35S]GTPγS Binding Assay
[35S]GTPγS binding was measured in 200 μl of buffer con-
taining 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM
MgCl2, 10 μM GDP, 1 mM dithiothreitol, 100 mM NaCl,
3 units/ml adenosine deaminase, 0.2 nM [35S]GTPγS,
0.004% CHAPS, 0.5% bovine serum albumin and increas-
ing concentrations of the ligands. Samples were started by
addition of the membrane suspension (5–10 μg protein/
tube) to the test tubes and incubated at 25°C for 30 min.
The assay was terminated by rapid filtration through
Whatman GF/B filters, pre-soaked in 50 mM Tris-HCl (pH
7.4) containing 5 mM MgCl2 and 0.02% CHAPS. Non-
specific binding of [35S]GTPγS was measured in the pres-
ence of 10 μM unlabelled GTPγS. After the filters were
washed, they were placed in scintillation vials containing
5 mL of Hydrofluor scintillation buffer and counted using
a Perkin Elmer Liquid Scintillation Analyzer. The EC50 val-
ues were determined using GraphPad Prism for all assays
[23].
Light and Fluorescent Microscopy
CHO or CHO A3 cells were seeded on a cover disk in a 6
well dish (250,000 cells per well). After the cells were
incubated for 24 hrs at 37°C, the medium was removed
and replaced with DMEM containing 10 μM of the 15 or
17. The cells were incubated for 1 h at 37°C and washed
one time with PBS. The images were taken with at 100×
manification using a Zeiss AxioVision D1 Imager
equipped with AxioVision 4.5 software.
Abbreviations
ADAC:  N6-[4-[[[4-[[[(2-aminoethyl)amino]carbo-
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AF488-TFP: Alexa-Fluor®  488 carboxylic acid, 2,3,5,6-
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CHAPS: 3-[(3-cholamidopropyl)dimethylammonio]-1-
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DMEM: Dulbecco's Modified Eagle Media; DMF: N, N-
dimethylformamide; DMSO: dimethyl sulfoxide; EDC: N-
(3-dimethylaminopropyl)-N'-ethylcarbodiimide; EDTA:
ethylenediaminetetraacetic acid; ERK: extracellular signal-
regulated kinase; ESI: electrospray ionization; GDP: gua-
nosine 5'-diphosphate; GPCR: G protein-coupled recep-
tor; [3H]CCPA: 2-chloro-N6-cyclopentyladenosine;
[3H]CGS21680: 2-[p-(2-carboxyethyl)phenylethyl-
amino]-5'-N-ethylcarboxamido-adenosine; HEK: human
embryonic kidney; HEPES: 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid; [125I]AB-MECA: [125I]-4-ami-
nobenzyl-5'-N-methylcarboxamideoadenosine; MALDI-
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mass spectrometry; NMR: nuclear magnetic resonance;
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oxytripyrrolidinophosphonium hexafluorophosphate.
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